Immix Biopharma (IMMX) reports Richard Graydon’s departure as immaterial event
Rhea-AI Filing Summary
Immix Biopharma, Inc. reported that as of July 17, 2026, Richard Graydon has been terminated and is no longer with the company. The company states that the departure is for reasons unrelated to his activities at Immix Biopharma.
Given his short tenure, management believes this change has no material effect on the business.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Terms
Emerging growth company, Exchange Act, pre-commencement communications
3 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Exchange Act regulatory
"under the Exchange Act (17 CFR 240.14d-2(b)"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.
pre-commencement communications regulatory
"Pre-commencement communications pursuant to Rule 14d-2(b)"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What event did Immix Biopharma (IMMX) report in this 8-K?
Immix Biopharma reported that Richard Graydon’s employment was terminated as of July 17, 2026. The company stated his departure is unrelated to his activities there and management believes it has no material effect on the business.
When did Richard Graydon leave Immix Biopharma (IMMX)?
Richard Graydon’s employment with Immix Biopharma ended as of July 17, 2026. This date marks the effective termination, and the company indicated that his short tenure limits any business impact.
Did Immix Biopharma (IMMX) link Richard Graydon’s termination to misconduct?
No. Immix Biopharma stated that Richard Graydon was terminated for reasons unrelated to his activities at the company. The disclosure does not allege misconduct and emphasizes no material business effect.
How material is Richard Graydon’s departure to Immix Biopharma (IMMX)?
Management believes Richard Graydon’s departure has no material effect on the business. They attribute this assessment to his short tenure at the company, suggesting limited operational impact.
Who signed the Immix Biopharma (IMMX) report about Richard Graydon’s termination?
The report regarding Richard Graydon’s termination was signed by Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. His signature reflects the company’s formal acknowledgment of the personnel change.